Abstract
The taxanes are anticancer cytotoxics that stabilise cellular microtubules. Two members, paclitaxel and docetaxel have substantial activity. One or both agents are widely accepted as evidence-based components of therapy for advanced breast, lung, and ovarian carcinomas. Paclitaxel has recently been approved in the USA for the adjuvant treatment of early stage node-positive breast carcinoma.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents, Phytogenic* / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / drug therapy
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Docetaxel
-
Female
-
Humans
-
Lung Neoplasms / drug therapy
-
Male
-
Ovarian Neoplasms / drug therapy
-
Paclitaxel* / analogs & derivatives*
-
Paclitaxel* / therapeutic use
-
Randomized Controlled Trials as Topic
-
Taxoids*
Substances
-
Antineoplastic Agents, Phytogenic
-
Taxoids
-
Docetaxel
-
Paclitaxel